The identification and validation of biomarkers for diagnosing Alzheimer’s disease (AD) and other forms of dementia are critically important. Until now ELISA measurement of β-amyloid(1–42), total Tau and phospho-Tau (181P) in cerebrospinal fluid (CSF) were the most advanced and accepted method to diagnose probable AD with high specificity and sensitivity. Today automated assays are available for quantitation of the Alzheimer’s disease (AD) biomarker amyloid-beta (Abeta42) and Tau proteins in cerebrospinal fluid. Analytical performance data for the novel Elecsys β-Amyloid(1-42) CSF and Elecsys Phospho-Tau(181P) CSF and Elecsys Total-Tau CSF ( pTau & tTau ) assays will be presented.
Implication for Alzheimer disease management is twofold. First the concordance of cerebrospinal fluid (CSF) biomarkers to the FDA approved amyloid-Positron Emission Tomography (PET) imaging method, providing an alternative to detect amyloid positivity in patient with mild cognitive decline being evaluated for AD ( fig above) will be demonstrated and second the ability of the biomarker to predict future cognitive decline in these patients will also be shown.
Welcome to Helsinki and International Congress on Quality in Laboratory Medicine 8-9 February, 2018 to learn more. Dr. Maryline Simon will give her presentation on Thursday 8 February, 2018.
Dr Maryline Simon
PhD, exec. MBA-HSG
Clinical Science Leader
Personalized Healthcare solutions ( PHCS)
Medical and Scientific Affairs
Roche Diagnostics International Ltd, Switzerland
Maryline is working for Roche Diagnostics as Clinical Science Leader in the team for medical and scientific affairs where she focuses on Alzheimer and Neurodegenerative diseases. She holds a PhD in Neurobiology from the ETH Zürich as well as an executive MBA from the University of St Gallen. Out of her academic career Maryline combines extensive research experiences in different industries with comprehensive knowledge in Business development. In her current Role she is responsible for providing scientific and operational leadership to achieve production of high quality clinical data to support the goals of the medical strategy plans and IVD development for Alzheimer and Neurodegenerative diseases.
International Congress on Quality in Laboratory Medicine 8-9 February 2018 Helsinki
Register now and ensure your participation to the most interesting congress in medical laboratory field in 2018. Scientific program deals with quality issues of laboratory medicine and advanced healthcare technologies. Two inspiring days with world class speakers will guarantee an unforgettable experience. Read more on www.labqualitydays.com